$0.50
+0.04 (+8.70%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RVPH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335Double Blind Safety and Efficacy of Brilaroxazine (RP5063)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Brilaroxazine · Other: Placebo | Schizophrenia | 690 | Feb 2025 | 2024-12-19 |
| RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderNCT01490086results2015-01-26Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total ScoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: RP5063, placebo, aripiprazole | Acute Schizophrenia, Schizoaffective Disorder | 234 | Mar 2013actual | 2025-08-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19